- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.
The conference symposium titled, "Multifunctional Nanoparticles for Drug Delivery and Imaging", will focus on the advancement of nanotechnology in the pharmaceutical and diagnostic industries. Dr. Zarzycki will highlight the distinct characteristics of Access' Cobalamin nanotechnology and the potential key role it will play in the future treatment of various diseases.
"The ACS is a leading organization comprised of scientific thought-leaders from the US and from around the world and we are honored to be invited to present the significant progress made with our Cobalamin technology at a conference symposium which includes many leading nanotechnology scientists," said Dr. Zarzycki, Director of Chemistry and Quality for Access Pharmaceuticals, Inc. He continued, "The strong interest surrounding our Cobalamin nanotechnology and the distinct revolutionary benefits it lends to large-molecule formulations, especially the unprecedented oral bioavailability, remains encouraging as we continue development of novel formulations for various disease applications."
Last month, Access Pharmaceuticals announced its pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of a currently marketed, proprietary injectable drug, utilizing its proprietary Cobalamin Oral Drug Delivery Technology. Although the name and the terms of the agreement have not been disclosed due to competitive reasons, management indicated that any successful formulation developed will be subject to a subsequent full-licensing agreement.
Cobalamin is Access' proprietary technology based upon the use of vitamin B12 for targeted delivery of drugs to disease sites and for oral drug delivery of drugs that otherwise have poor oral bioavailability. Access has focused its Cobalamin product development program on the oral delivery of insulin and human growth hormone, two peptides which currently can only be given by injection. Since presenting promising results at a major conference in mid-2008, Access has made substantial improvements to the formulation technology. A new Cobalamin-coated insulin-containing nanoparticle formulation delivered orally provided a pharmacological response (lowering of blood glucose levels in an animal model of diabetes) greater than 80% of that achieved by insulin delivered subcutaneously. This represents a substantial oral bioavailability, indicating that this formulation has potential for clinical development and ultimate commercialization. Adaptation of this technology has provided a Cobalamin human growth hormone formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model. Access continues to move both products towards clinical development.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
About Access Pharmaceuticals
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
For more information, please click here
Director of Investor Relations
Copyright © Access PharmaceuticalsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene makes rubber more rubbery May 23rd, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016